On August 9, 2024, Avidity Biosciences announced positive initial data from their EXPLORE44™ clinical trial, that is assessing the safety and efficacy of their investigational therapy, AOC 1044 in people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).
EXPLORE44 is a placebo-controlled study that enrolled 40 healthy volunteers and 24 participants with DMD44, ages seven to 27 years old. AOC 1044 is designed to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in people living with DMD44.
To read the full community letter and press release, please click here.
